Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 3,620 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult-onset Diabetes Clear all
Not listed Not applicable Interventional

Blood Glucose Differences Using CGMs Between the Left and Right Arm in Patients With Diabetes

NCT05849428
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Freestyle Libre 3
Device
Lead sponsor
University of the Pacific
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Stockton, California
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 3 Interventional Results available

Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin

NCT02984644
View directory record Official record
Conditions
Type II; Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 7, 2026, 10:27 AM EDT
Recruiting Phase 4 Interventional

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

NCT05390892
View directory record Official record
Conditions
Type2Diabetes, ASCVD
Interventions
SGLT2 inhibitor, GLP-1 receptor agonist
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
36
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 3 Interventional

Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)

NCT00288236
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Rimonabant (SR141716), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

NCT01147250
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Lixisenatide (AVE0010), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years and older
Enrollment
6,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
200
States / cities
Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 160 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 7, 2026, 10:27 AM EDT
Completed No phase listed Observational Results available

Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity

NCT04114903
View directory record Official record
Conditions
Type 2 Diabetes, Obesity, Cannabis Use, Insulin Sensitivity
Interventions
Study A: Single use of cannabis flower product, Study B: Ad libitum cannabis use for four weeks or no cannabis use
Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
21 Years to 40 Years
Enrollment
233 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 7, 2026, 10:27 AM EDT
Terminated Phase 1 Interventional

Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects

NCT01755442
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Placebo, AMG 151
Other · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Results available

Characteristics of Glargine in Type 2 Diabetics

NCT00574912
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo, Insulin Glargine 0.5 u/kg body wt SC, Insulin Glargine 1.0 u/kg body wt SC, Insulin Glargine 1.5 u/kg body wt SC, Insulin Glargine 2.0 u/kg body wt SC
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 7, 2026, 10:27 AM EDT
Suspended Phase 2 Interventional

A Study Evaluating Safety and Efficacy of BIOD 531 Compared to Humalog® Mix 75/25 in Subjects With Type 2 Diabetes

NCT02446028
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
BIOD-531, Humalog® Mix 75/25
Drug
Lead sponsor
Biodel
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Bradenton, Florida • Roswell, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 7, 2026, 10:27 AM EDT
Completed No phase listed Observational

Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims

NCT06659744
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
New use of semaglutide injection, New initiation of sitagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
158,310 participants
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Circuit Training and Motivational Interviewing to Reduce Type 2 Diabetes in Youth

NCT00693511
View directory record Official record
Conditions
Obesity and Type 2 Diabetes
Interventions
Circuit Training, Circuit training + motivational interviewing
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
14 Years to 18 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Not applicable Interventional

A Comprehensive Community Approach for Diabetes Prevention and Care for a Vulnerable Population in Galveston

NCT05097534
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
iDSMES, Standard of Care
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
13 Years to 84 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 7, 2026, 10:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mil Familias Cohort Establishment: a Study to Understand Determinants of Diabetes and Its Complications Among US Latinos

NCT03830840
View directory record Official record
Conditions
Type2 Diabetes Mellitus, Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
7 Years and older
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Risk Factors for Diabetes Complications in Primary Care

NCT00482768
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Practice Facilitation
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
2,493 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 7, 2026, 10:27 AM EDT
Terminated No phase listed Observational

Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy

NCT00579150
View directory record Official record
Conditions
Birth Defects, Type 2 Diabetes, Preterm Birth
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Not applicable Interventional

Telehealth Lifestyle Program for Black Adolescent Girls at Risk for Type 2 Diabetes

NCT05396443
View directory record Official record
Conditions
Obesity, Childhood, Type2Diabetes
Interventions
Black Girls for Wellness Telehealth
Behavioral
Lead sponsor
Cornell University
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pfizer/IVGTT/Ziprasidone/Olanzapine

NCT00205725
View directory record Official record
Conditions
Schizophrenia, Type 2 Diabetes Mellitus
Interventions
Ziprasidone, Olanzapine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 4 Interventional Results available

Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy

NCT02299050
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cycloset
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 69 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 7, 2026, 10:27 AM EDT
Recruiting Phase 4 Interventional

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

NCT05708859
View directory record Official record
Conditions
Type II Diabetes, Atherosclerosis
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Matthew J. Budoff
Other
Eligibility
40 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Not applicable Interventional Results available

Reinforcement Learning in Diabetes Mellitus Trial

NCT04473326
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Medication Adherence
Interventions
Reinforcement Learning
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 84 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 7, 2026, 10:27 AM EDT
Terminated Phase 2 Interventional Results available

Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin

NCT00701935
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
placebo, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Temple, Arizona • Colorado Springs, Colorado • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 1 Interventional

To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes

NCT01176097
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD5658, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 7, 2026, 10:27 AM EDT
Completed Phase 3 Interventional Results available

A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

NCT04605991
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
LY900014, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
30
States / cities
Concord, California • Escondido, California • Fresno, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 7, 2026, 10:27 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Insulin and Insulin Pulses During Fasting

NCT06424015
View directory record Official record
Conditions
PreDiabetes
Interventions
Intralipid and heparin, Saline
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 7, 2026, 10:27 AM EDT